T
Trinity Biosystems
Oral therapeutic protein and vaccine development platform
About Trinity Biosystems
Trinity Biotech develops, manufactures, and distributes diagnostic products for the clinical laboratory and point-of-care segments of the global healthcare market. The company was co-founded by Ronan O'Caoimh in June 1992, who initially served as CFO and later as CEO and Chairman. John Gillard took over as CEO and President in December 2023, having joined as CFO in 2020 after holding senior financial roles at companies like Google and ION Investment Group. Dr. Jim Walsh, another key figure, joined in 1995 and has held various roles including COO and Chief Scientific Officer.
The company's business model focuses on developing and providing high-quality, niche diagnostic solutions with differentiated technology. Its product portfolio is diversified across several areas. Key segments include tests for Haemoglobins (for diagnosing diabetes and haemoglobin variants), Autoimmunity, and Point-Of-Care infectious disease testing, such as for HIV. The company generates significant recurring revenue through the sale of reagents and consumables required for its several thousand installed instruments globally. Additionally, Trinity Biotech operates two steady niche businesses: Fitzgerald, a specialty life sciences supply business, and a Clinical Chemistry division that supplies high-value diagnostic biologicals.
Trinity Biotech's product offerings, available through distributors like Fisher Scientific, include test kits for infectious diseases, glycated hemoglobin (HbA1c) calibrators and controls for diabetes monitoring, and various clinical chemistry reagents. The company has shifted its revenue base away from older ELISA technology and continues to innovate, with products like a rapid antigen test for COVID-19 and a new automated testing instrument for autoimmunity in its pipeline.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 2002
- Headquarters
- Menlo Park, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Health Diagnostics, Hard Tech, DT and LS, science-based
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Nov 2009 | $7.5M | — | Lilly Ventures | — |
| SERIES B✓Equity / VC | Jul 2006 | $21M | $84M | Tenex Greenhouse Ventures · Amgen Ventures · Sanderling Ventures | — |
Growth signals
Latest recorded traffic for Trinity Biosystems is 0 monthly website visits. Trinity Biosystems's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Sanderling Ventures- TVTenex Greenhouse Ventures
Amgen Ventures
Series B and later1 investor entered at this stage
Lilly Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Trinity Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Trinity Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.